Trials / Completed
CompletedNCT00924105
Safety, Tolerability and Pharmacodynamics of CYT013-IL1bQb in Patients With Type 2 Diabetes
A Two-Stage Randomized Placebo-controlled Ascending Dose Phase I/ IIa Study to Evaluate Safety, Tolerability, Pharmacodynamic Effects and Preliminary Efficacy of an Anti-Interleukin 1 Beta Vaccine (CYT013-IL1bQb) in Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Cytos Biotechnology AG · Industry
- Sex
- All
- Age
- 18 Years – 69 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical trial is to test safety and tolerability of a vaccine targeting Interleukin-1 beta in patients with type 2 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CYT013-IL1bQb | s.c. injection |
| DRUG | Placebo | s.c. injection |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2011-11-01
- Completion
- 2011-11-01
- First posted
- 2009-06-18
- Last updated
- 2012-02-13
Locations
3 sites across 2 countries: Germany, Switzerland
Source: ClinicalTrials.gov record NCT00924105. Inclusion in this directory is not an endorsement.